Anna Jonasova

7PUBLICATIONS
47CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyHaematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 07, 2026
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.

Amer M Zeidan, Valeria Santini, María Díez-Campelo

|May 07, 2025
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Amy E DeZern, Sylvain Thepot, Stephane de Botton

|Jan 05, 2024
Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms.

Monika Kaisrlikova, David Kundrat, Pavla Koralkova

|Sep 07, 2022
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.

Anne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth

|Jul 07, 2022
G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.

Tomáš Stopka, Lubomír Minařík, Nina Dusilková

|May 03, 2022
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.

Monika Kaisrlikova, Jitka Vesela, David Kundrat

Pageof 2

Frequent Collaborators

2 joint publications

Valeria Santini

2 joint publications

Monika Kaisrlikova

2 joint publications

Jitka Vesela

2 joint publications

David Kundrat